1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. PCAS
  6. News
  7. Summary
    PCA   FR0000053514

PCAS

(PCA)
  Report
Real-time Euronext Paris  -  11:20 2022-08-11 am EDT
7.500 EUR   -4.82%
07/29PCAS : Net sales as of june 30, 2022
GL
07/29PCAS : Net sales as of june 30, 2022
GL
07/29PCAS : 2nd quarter earnings
CO
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

PCAS : US patent granted for PCAS new Cinacalcet production process

04/14/2016 | 04:22am EDT

Cinacalcet_press release


PCAS press release



April 12th, 2016 - US patent granted for PCAS new Cinacalcet production process



PCAS is committed to the development of its proprietary products catalogue as a way to increase its business performance. In the field of Active Pharmaceutical Ingredients (API), this commitment is put in place by the development of innovative and cost-effective processes for the production of APIs that PCAS will be able to offer to customers in the coming future.

The API, Cinacalcet is a calcimimetic agent used primary for the treatment of hyperparathyroidism primary or secondary. Hyperparathyroidism is a condition in which the parathyroid glands in the neck produce too much parathyroid hormone (PTH), which can lead to bone and joint pain and deformities of the arms and legs. Cinacalcet is sold under the brand Mimpara in Europe and Sensipar in the USA and it is formulated with 30mg, 60mg or 90mg strengths.

Cinacalcet was launched by Amgen in 2004 and has reported worldwide sales of 1 415 M$ in 2015 under the Mimpara/Sensipar brands. The sales figures show an increase of 22% on a year-to-year base.


PCAS has developed an innovative and cost-competitive process for the production of Cinacalcet, taking advantage of its strong know-how on Wittig chemistry but adapted to prepare Cinacalcet on a convergent and direct manner. The process takes advantage of a key product produced in-house at PCAS.

PCAS had filed for patent protection for this process and are pleased to announce that the US Patent Office has granted PCAS' application the US patent number 9,290,439 that has been delivered on March 22nd, 2016.

The equivalent European patent application has a positive review by the European Patent Office, anticipating a smooth delivery of the patent.

PCAS has filed for regulatory approval in major markets, obtaining already the ASMF dossier for entering the European regulated market.


All these actions reinforce PCAS position as a trusted Active Pharmaceutical Ingredients (APIs) supplier, having worldwide regulatory filing capacity to support our customers' product development. This position is confirmed by the regular audits of PCAS production sites by several national authorities in support of the large number of products currently on the market as well as new product launches.

PCAS' multi-client catalogue of APIs lists more than 40 APIs regularly produced in our four GMP-compliant production sites. On the regulatory side, the products of the catalogue are supported by 29 US DMFs, 25 European DMFs, 15 European CEPs, 10 Japanese DMFs, 10 Canadian DMFs, among others successful regulatory filings including several new dossiers in progress in China.


PCAS SA issued this content on 12 April 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 14 April 2016 08:21:20 UTC

Original Document: http://www.pcas.com/content/download/4281/70365/version/2/file/Cinacalcet_press_release.pdf


© Publicnow 2016
All news about PCAS
07/29PCAS : Net sales as of june 30, 2022
GL
07/29PCAS : Net sales as of june 30, 2022
GL
07/29PCAS : 2nd quarter earnings
CO
05/13PCAS : Net sales as of march 31, 2022
GL
05/13PCAS SA Reports Net Sales for the Period of March 31, 2022
CI
05/13PCAS : Net sales as of march 31, 2022
GL
04/29PCAS : Release of the 2021 Universal Registration Document (URD)
GL
02/24PCAS : 2021 annual results
GL
02/24PCAS SA Reports Earnings Results for the Full Year Ended December 31, 2021
CI
02/24PCAS : Annual results
CO
More news
Financials
Sales 2021 187 M - -
Net income 2021 -40,5 M - -
Net Debt 2021 62,2 M - -
P/E ratio 2021 -2,85x
Yield 2021 -
Capitalization 103 M 106 M -
EV / Sales 2020 1,05x
EV / Sales 2021 0,95x
Nbr of Employees 1 092
Free-Float 14,1%
Chart PCAS
Duration : Period :
PCAS Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PCAS
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Managers and Directors
Philippe Clavel Chief Executive Officer
Eric Moissenot General Director-Finance & Administration
Pierre Luzeau Chairman
Gérard Guillamot Scientific Director
Jacqueline Lecourtier Independent Director
Sector and Competitors
1st jan.Capi. (M$)
PCAS-6.19%112
JOHNSON & JOHNSON-2.30%448 722
ELI LILLY AND COMPANY9.03%289 433
PFIZER, INC.-18.22%280 264
ROCHE HOLDING AG-16.39%278 152
ABBVIE INC.4.93%249 196